2024
Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review
de Beur S, Dahir K, Imel E, Zanchetta M, Williams A, Li Z, Webb N, Crowe V, Johnson B, Carpenter T. Healthcare Resource Use Associated With Tumor-Induced Osteomalacia: A Literature Review. The Journal Of Clinical Endocrinology & Metabolism 2024, dgae431. PMID: 38913723, DOI: 10.1210/clinem/dgae431.Peer-Reviewed Original ResearchTumor-induced osteomalaciaHealthcare resource useResection outcomesCase reportHigher probability of tumor recurrenceSecrete fibroblast growth factor 23Probability of tumor recurrenceAssociated with tumor-induced osteomalaciaFibroblast growth factor 23Symptoms to diagnosisHealthcare resource burdenTumor recurrenceParaneoplastic syndromeTumor resectionAssociated with greater usePharmacological treatmentDisease characteristicsImaging testsPatientsMusculoskeletal symptomsTargeted literature reviewResource useOrthopedic surgeryProgressive disabilityMean time
1995
Secretion of a Large Molecular‐Weight Form of Insulin‐Like Growth Factor by a Primary Renal Tumor
Korn E, van Hoff J, Buckley P, Daughaday W, Carpenter T. Secretion of a Large Molecular‐Weight Form of Insulin‐Like Growth Factor by a Primary Renal Tumor. Pediatric Blood & Cancer 1995, 24: 392-396. PMID: 7715546, DOI: 10.1002/mpo.2950240610.Peer-Reviewed Original ResearchConceptsPrimary renal tumorsIGF-IIRenal tumorsInsulin-like growth factor-II levelsInsulin-like growth factorIGF-II contentPost-operative serumTotal IGF-IIFactor II levelsPediatric renal tumorsLarge molecular weight formsPreoperative serumAbdominal massTumor resectionII levelsBiochemical hypoglycemiaHypoglycemiaTumor tissueTumorsGrowth factorResectionMolecular weight formsSerumPatientsHistology